Q2 2026 13F · SEC CIK 1545692
Nvp Associates, LLC
Investment managerFiled 2026-08-07 for Q2 2026. Open the filing ↗ · All SEC filings ↗
- Reported 13F value
- $328.2M
- Reported positions
- 7
- Top holdings a year, 3 yrs
- +31.4%
- Average holding period
- 1.3 yrs
Nvp Associates, LLC is an investment manager that reported 7 positions worth $328.2M in its Q2 2026 13F, filed 2026-08-07. Its largest holdings were Mbx Biosciences Inc (MBX, 35.9%), Avalyn Pharmaceuticals Inc (AVLN, 22.8%), Omada Health, Inc. Common Stock (OMDA, 16.9%). A portfolio copying its top holdings returned 31.4% a year over the last 3 years, against 19.9% for the S&P 500.
Nvp Associates, LLC holdings all 7 positions.
Weights are shares of the filer's total reported 13F value, compared with Q1 2026. Share changes may reflect splits; weight changes also reflect price moves. A 13F shows long US-listed positions only, up to 135 days after the fact.
| Stock | % of 13F value | Share change | Reported value |
|---|---|---|---|
| MBXMbx Biosciences Inc | 35.9% | +0.0% | $117.9M |
| AVLNAvalyn Pharmaceuticals Inc | 22.8% | — | $74.7M |
| OMDAOmada Health, Inc. Common Stock | 16.9% | +0.0% | $55.6M |
| ZBIOZenas Biopharma Inc | 14.2% | +0.0% | $46.7M |
| SNOWSnowflake Inc | 8.9% | — | $29.2M |
| GROVGrove Collaborative Hold Inc | 1.2% | +0.0% | $4.0M |
| ONDSOndas Inc | 0.0% | — | $129K |
What Nvp Associates, LLC bought and sold in Q2 2026, against Q1 2026.
New positions
- AVLN Avalyn Pharmaceuticals Inc22.8% of 13F
- SNOW Snowflake Inc8.9% of 13F
- ONDS Ondas Inc0.0% of 13F
Added to
No position grew by more than 5%.
Reduced
No position shrank by more than 5%.
Sold out
- BLLN Billiontoone Incwas 23.0%
Share counts compared with the Q1 2026 13F; a split also changes share counts.
How the holdings did against the S&P 500.
- 1 year
- +116.8% /yr
- S&P 500 +20.1%
- 3 years
- +31.4% /yr
- S&P 500 +19.9%
- 5 years
- —
A portfolio of the filer's 20 largest 13F positions, weighted by value, bought the trading day after each 13F was filed and held until the next one was: what copying this filer could have earned. 13Fs show long US-listed positions only, so this is an estimate of the stock picks, not the fund's reported returns.
Reported 13F value by quarter.
| Quarter | 13F value | Positions |
|---|---|---|
| Q2 2026 | $328.2M | 7 |
| Q1 2026 | $176.2M | 5 |
| Q4 2025 | $255.2M | 6 |
| Q3 2025 | $166.1M | 5 |
| Q2 2025 | $184.2M | 7 |
| Q1 2025 | $112.2M | 6 |
| Q4 2024 | $186.9M | 7 |
| Q3 2024 | $176.1M | 8 |
| Q2 2024 | $91.3M | 6 |
| Q1 2024 | $125.9M | 6 |
| Q4 2023 | $112.1M | 6 |
| Q3 2023 | $111.7M | 8 |
Questions about Nvp Associates, LLC's portfolio
What stocks does Nvp Associates, LLC own?
Nvp Associates, LLC's latest 13F, for Q2 2026 and filed Aug 7, 2026, lists 7 positions worth $328.2M. The largest are Mbx Biosciences Inc (MBX) at 35.9%, Avalyn Pharmaceuticals Inc (AVLN) at 22.8%, Omada Health, Inc. Common Stock (OMDA) at 16.9%, Zenas Biopharma Inc (ZBIO) at 14.2% and Snowflake Inc (SNOW) at 8.9%.
What did Nvp Associates, LLC buy last quarter?
In Q2 2026, Nvp Associates, LLC added a new position in Avalyn Pharmaceuticals Inc (AVLN), a new position in Snowflake Inc (SNOW) and a new position in Ondas Inc (ONDS), compared with its Q1 2026 filing.
What did Nvp Associates, LLC sell last quarter?
In Q2 2026, Nvp Associates, LLC sold all of Billiontoone Inc (BLLN), compared with its Q1 2026 filing.
How has Nvp Associates, LLC's portfolio performed?
A portfolio copying Nvp Associates, LLC's 20 largest 13F holdings each quarter, from the day each filing was public, returned +31.4% a year over the last 3 years, against +19.9% for the S&P 500. Over 1 year: +116.8% against +20.1%.
When is Nvp Associates, LLC's next 13F filing due?
13F filings are due 45 days after each quarter ends. Nvp Associates, LLC's filing for the quarter ending Sep 30, 2026 is due by Nov 14, 2026; this page updates the day after it is published.